{"created":"2023-05-15T14:42:59.126461+00:00","id":58895,"links":{},"metadata":{"_buckets":{"deposit":"9ffb52f1-bf55-4907-8f81-2376f17baa0b"},"_deposit":{"created_by":1,"id":"58895","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"58895"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00058895","sets":["11"]},"author_link":["586887","586886"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"10","bibliographicPageEnd":"1395","bibliographicPageStart":"1391","bibliographicVolumeNumber":"45","bibliographic_titles":[{"bibliographic_title":"癌と化学療法"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"核医学分野では、個別化医療に直結する「theranostic（診断と治療の一体化）」なプローブが続々と開発され、分子標的によるPET/SPECT核種による診断と核種の付け替え（治療用核種への書換）による治療・標的アイソトープ治療（targeted radioisotopu therapy:TRT）の新時代を迎えている。近年、α線核種が臨床導入され、従来のβ線核種を凌駕する治療効果を示している。α線製剤としてラジウム223が前立腺癌領域で初めて臨床応用され、その高い治療効果（高LET、高RBE）と安全性から幅広い注目を浴び、次なるα線核種としてアクチニウム225やアスタチン211の医学利用も期待されている。現時点ではα線TRTの臨床応用は少ないが、国内でも救数のTRT臨床治験が始まり、近年臨床応用が期待されている。最新のTRT事情と将来展望を概説した。","subitem_description_type":"Abstract"}]},"item_10004_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"癌と化学療法社"}]},"item_10004_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0385-0684","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"東, 達也"}],"nameIdentifiers":[{"nameIdentifier":"586886","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東 達也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"586887","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"標的アイソトープ治療の現状と将来展望","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"標的アイソトープ治療の現状と将来展望"}]},"item_type_id":"10004","owner":"1","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-10-17"},"publish_date":"2018-10-17","publish_status":"0","recid":"58895","relation_version_is_last":true,"title":["標的アイソトープ治療の現状と将来展望"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T22:11:00.364546+00:00"}